Articles tagged with Cancer Medication
Researchers at the University of Missouri have developed a new cancer detection and treatment method using nanoparticles that target specific receptors on tumor cells. The gold nanoparticles can be targeted to prostate, breast, or lung cancer cells, providing valuable imaging and therapeutic tools for early cancer detection and therapy.
A global consortium has cataloged genetic changes of 50 common cancers, making it possible to sequence partial or full genomes as part of clinical evaluation. This will enable targeted treatments and help understand why some treatments work and others do not.
Researchers at MIT discovered that tumor cells develop enhanced DNA repair pathways to evade cell death when treated with cisplatin. This finding offers insights into the mechanisms of resistance and may lead to the development of more effective cancer treatments.
Researchers from Ontario Cancer Institute and US scientists have discovered a compound that blocks protein BCL6, a cancer-causing culprit in about half of all non-Hodgkins lymphoma cases. This breakthrough accelerates developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.
Researchers at the University of North Carolina found that a common cancer drug can activate an Epstein-Barr virus infection, making cancer cells more susceptible to antiviral medications. This discovery may lead to new treatment strategies for EBV-related cancers.
A new discovery reveals that drugs affecting DNA methylation could reverse autism's effects, improving diagnosis and treatment options. The study identified specific genes altered in autistic individuals with severe language deficits, paving the way for personalized therapies.
Researchers at IRB Barcelona have developed a new method to study intrinsically disordered proteins, crucial for designing drugs against Alzheimer's disease and prostate cancer. The approach uses computational predictions and laboratory experiments to obtain structural information about dynamic proteins.
Researchers have designed an experimental drug called OSU-CG12 that kills cancer cells by choking off their energy supply. The agent targets a survival mechanism used by many types of cancer, and its efficacy is 10 times better than a comparable drug, resveratrol.
A new oral anti-cancer drug, vorinostat, is safe to combine with short-term palliative radiotherapy in patients with advanced pelvic cancer. The therapy may enhance the effect of radiotherapy and could become a component of long-term curative treatment. Patients showed tumor response and reduced side effects when treated with vorinostat.
A Mount Sinai study of over 400,000 people found that high fruit and vegetable consumption reduces cancer risk by only 3%, with benefits limited to certain populations. The researchers concluded that the association is weak and may not justify increased dietary recommendations.
Researchers at MGH Cancer Center found reversible drug tolerance in some cancer cells, associated with changes in chromatin structure. This nongenetic mechanism may be a fundamental property of many tumor cell populations, and potential therapeutic strategies are being explored.
A new study found that certain HIV drugs can inhibit a retrovirus linked to prostate cancer and chronic fatigue syndrome. Raltegravir and other antiviral medications showed effective virus replication inhibition, suggesting possible treatments for these devastating illnesses.
A new drug, PD-0332991, has been found to effectively block the growth of glioblastoma cells in laboratory tests and animal studies. The agent targets specific molecules that drive cell division in cancer cells, offering a potential new treatment option for this deadly form of brain cancer.
Researchers have discovered that heat shock protein 90 inhibitors could be effective in treating cardiovascular disease by blocking chronic inflammation. By targeting NFкB, they aim to find a less toxic alternative to existing anti-inflammatory agents.
People with diabetes undergoing cancer surgery are at a higher risk of death in the month following their operations. The study, led by Johns Hopkins researchers, found that newly diagnosed cancer patients with Type 2 diabetes have a 50% greater risk of mortality after surgery, particularly for colorectal and esophageal tumors.
Researchers developed a strategy to overcome the issue, highlighting the importance of communication between healthcare providers. The study showed that changing drug therapy at an early stage can help patients get the full benefit of tamoxifen treatment, leading to improved breast cancer efficacy.
A randomized trial found that octreotide acetate did not reduce the incidence or severity of diarrhea in patients with anorectal cancer. The study included 215 patients who received either a placebo or long-acting octreotide before and during radiation therapy, but no significant differences were observed between groups.
Researchers at UCSF have discovered a key cellular defect that can lead to cancer susceptibility and are developing a new generation of inhibitory drugs to correct this defect. The new drug, PP242, has shown promising results in clinical trials and holds promise for treating various types of cancer.
Researchers have made significant progress in treating spinal muscular atrophy with targeted gene therapy, improving muscle strength and coordination. Additionally, a new approach to treating Duchenne muscular dystrophy heart disease has been discovered using membrane-sealing poloxamer. Furthermore, a cancer drug has shown promise in m...
Anti-angiogenic drugs used to treat cancer may improve immune responses in tissues affected by chronic infection or inflammation, increasing effectiveness of conventional treatments for leishmaniasis and other globally important diseases.
A study of 792 patients with multiple myeloma found that vertebroplasty significantly reduced pain intensity, medication usage, and disability. The procedure improved mobility in nearly half of the patients, who also reported considering vertebroplasty again if needed.
Scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with normal cells, improving the accuracy of anti-cancer drug screenings. This new 'cell-specific in vitro bioluminescence imaging' (CS-BLI) technique can identify compounds ...
A large multicenter trial in Japan found that patients with early gastric cancer who received H. pylori antibiotics after surgical resection had a significantly lower risk of developing gastric cancer. Certain strains of H. pylori may carry an increased risk of developing gastric cancer, but more research is needed to fully understand ...
Researchers at Berkeley Lab have found a novel way to influence cancer cell behavior using physical forces, which may lead to new cancer treatments. The study reveals that the EphA2/ephrin-A1 receptor-ligand complex can sense mechanical properties of its environment.
Clinicians often miss vital symptoms and underestimate their severity in clinical trials, leading to under-reporting of adverse events. Patient self-reporting can enhance symptom and event data quality and give patients a voice in healthcare decision-making.
Researchers found that fulvestrant's anti-cancer effects are enhanced when cells express high levels of cytokeratins CK8 and CK18, structural proteins involved in estrogen regulation. The study suggests that testing for these proteins could help doctors decide whether fulvestrant should be prescribed to patients.
Researchers have found a way to enhance drug delivery to solid tumors by temporarily breaking down blood vessel walls, allowing drugs to reach the tumor more efficiently. This breakthrough could lead to improved treatment options for previously intractable solid cancers.
Researchers at the University of Florida have found that papaya extract thwarts the growth of cancer cells in lab tests, boosting the production of key signaling molecules and suggesting possible therapeutic strategies. The extract did not show toxic effects on normal cells, consistent with reports from indigenous populations.
Recent clinical and scientific advancements in nervous system cancers have improved our understanding of molecular changes and new therapies for patients. The March issue of Archives of Neurology features articles on various topics, including increased melanoma risk among Parkinson's disease patients and new insights into glioma risk.
A recent study from UT Southwestern Medical Center found that combination therapy yielded better results than individual drugs in treating enlarged prostate. The treatment, which combined dutasteride and tamsulosin, reduced the risk of BPH progression by 25% and PSA levels by 50%.
Researchers found that estrogen inhibits MLK3, a protein that causes normal cell death, leading to uncontrolled growth of cancer cells and resistance to chemotherapy. This discovery could lead to new cancer-fighting drugs.
Researchers have identified a new biomarker that defines a subtype of aggressive breast cancer and offers potential for targeted therapy. The biomarker, associated with poorer outcomes, can be inhibited by a protein called Mesd, which has shown promise in slowing tumor growth and reducing side effects.
Researchers have developed two potential drug candidates that block cancer-promoting pathways in novel ways. The peptides offer a new approach to interfere with the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways.
A new study by Johns Hopkins scientists found that Notch-blocking drugs can kill brain cancer stem cells in mice, with a 70% reduction rate. However, further experiments suggested that additional therapies or increased dosage of Notch-blocking drugs may be necessary to target all cancer stem cells.
Researchers have developed a nanotechnology approach that allows for targeted and simultaneous delivery of cancer-killing drugs and genetic drugs to prevent resistance. The treatment shows promise in eliminating side effects associated with chemotherapy.
Researchers identified signaling molecules linked to B cell actions and solid tumor growth, suggesting a previously used lymphoma treatment may be effective against other solid tumors. The discovery opens up new therapeutic targets and combinations of chemotherapy with immune system-modifying drugs.
A European study finds inadequate access to opioid-based pain relief for cancer patients, with some countries restricting essential medicines. The authors conclude that restrictive regulations hinder medical care and recommend revising laws to improve accessibility.
Researchers have developed a new tool to understand how cancers grow and identify novel cancer drugs. By analyzing human prostate tissue and engineering specific genetic changes, scientists can create cancer cells from stem cells, providing precise targets for treatment.
Scientists created oil droplets that can solve complex mazes using pH gradients, potentially helping cancer drugs reach tumors and nano-machines move accurately. This technology could be used to design new anti-cancer drugs and improve the navigation of futuristic nano-machines.
Researchers at U-M Comprehensive Cancer Center found a third protein, TIN2, that overrides Fbx4 by binding to TRF1, stabilizing it and keeping telomere length in control. This finding could lead to developing a drug to block Fbx4, impacting all cancer types.
Researchers found that sorafenib therapy can reduce large kidney tumors by up to 40% prior to surgery, making patient recovery less challenging. The study's results suggest a promising new treatment option for patients with advanced kidney cancer.
Researchers found that erlotinib is marginally cost-effective for treating patients with advanced non-small cell lung cancer, with an incremental cost-effectiveness ratio of $94,638 per life-year gained. The treatment's cost-effectiveness may be improved through targeted patient selection and biomarker-guided therapy.
Scientists have visualized a donut-shaped structure of an enzyme involved in degrading proline, a key amino acid in metabolism. This discovery will aid in understanding the enzyme's function and developing drugs to inhibit its activity.
A novel anti-cancer drug has been developed by binding to a molecular switch found in cancer cells and blood vessels, keeping it in the 'off' position. The new approach uses scaffold-based chemistry and supercomputer technology to identify potential drug candidates that can halt tumor growth.
Researchers at UT Southwestern Medical Center discovered a single gene mutation that induces endometrial cancer, which can be treated with a specific drug therapy. The study found that women with this mutation may respond well to 'rapalogs' and could benefit from targeted treatment.
The study found that molecular pathways involved in women's lung cancer are less complex than those in men, while elderly patients over 70 have a low-risk profile for long-term survival. The findings may help explain why certain groups of patients do better than others despite having the same disease.
Triapine regimen provides significant reduction in cancer disease and cancer control, shows great promise for patients at high risk of relapse and death. The study's complete response rate was observed and no disease progression documented through 18 months of median follow-up.
Scientists have identified a new target for cancer treatment, protein STAT3, in neurofibromatosis-1 (NF1) patients. Blocking STAT3 slows tumor growth and increases cell death in mice, offering a promising approach to treat brain tumors.
A University of Adelaide pathologist has sounded a warning about the dangers of herbal medicines, which can cause serious illnesses, exacerbate pre-existing health problems, or result in death if taken in excess or combined with prescription drugs. The study analyzed 251 Asian herbal products and found high levels of toxic substances.
A new study published in Journal of Clinical Oncology found that pazopanib slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54%. The drug targets multiple pathways within cancer cells, inhibiting blood vessel development. Common side effects include diarrhea, hypertension, and weight loss.
The CYCORE project aims to aggregate data from clinical trials, patient records, and behavioral data to study cancer treatment effectiveness. By analyzing this data, researchers hope to better understand which treatments work best for specific patients and develop more effective prevention and recovery strategies.
Researchers have identified an enzyme that can remove the oncogene WT1 from cancer cells, leading to promising targets for treatments. The discovery of protease HtrA2 has shed new light on how levels of WT1 are controlled in cancer.
Research on patient access schemes found that refunds were not always passed on to primary care trusts, leading to financial losses. The study also identified the need for flexibility in processing claims and standardized templates to streamline administration.
Over a two and half year period, the FDA approved 53 new oncology and hematology drugs, including 39 receiving regular approval and nine accelerated approval. Most approvals were based on single-arm, non-randomized controlled trials.
Researchers from EMBL have discovered the molecular structure of a key protein involved in cellular communication systems that are affected in neurodegeneration, cancer and cardiovascular disease. The study provides insights into how this protein functions and how it can be targeted with drugs to develop new treatments.
A proteomics study reveals prohibitin1 as a protein involved in taxane resistance, which could be targeted with drugs to make cancers more susceptible to chemotherapy. Suppressing prohibitin1 may also serve as a biomarker for predicting patient response to chemotherapy.
Researchers at Dana-Farber Cancer Institute discovered a gene activity signature predicting high cancer recurrence risk in breast tumors treated with chemotherapy drugs. The study suggests that these tumors may still be vulnerable to other types of chemotherapy agents.
Researchers found that identifying patients with a small number of tumor cells harboring an overabundance of MET even before treatment can produce longer remissions when treated with combination drugs. This suggests that targeting these cells with additional drugs may be beneficial in preventing resistance.
The study analyzed data from 15 trials involving 3,452 women, finding that chemoradiotherapy improved survival rates compared to radiotherapy alone. This treatment also reduced the chance of cancer recurrence and spread.
Researchers at Loyola Medicine found that sun damage silences protein kinase C gene, allowing cancerous cells to grow and divide unchecked. The study could lead to development of new drugs to shrink tumors.